OR WAIT null SECS
August 11, 2023
Novartis has completed its acquisition of biopharma company Chinook Therapeutics.
The guidance can help both applicants and manufacturers limit the mutagenic and carcinogenic potential of NDSRIs.
The new drug could be a powerful tool for patients suffering depressive symptoms after birth.
August 10, 2023
The site was acquired by AGC Biologics in July 2020, and the Milan location is the first cell and gene therapy site approved in Europe for GMP manufacturing of clinical and commercial supplies.
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
August 09, 2023
SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).
August 08, 2023
The investigational drug was developed to activate a novel uptake pathway, allowing antineoplastic drugs to combat solid tumors more successfully.
The bioreactors can integrate with Emerson’s DeltaV PK Controller in addition to S-Series and M-Series controllers.
Lower levels of an active ingredient may result in unexpected pregnancies.
August 07, 2023
BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.